MedDataX Logo

Effectiveness of the Use of the Nintendo Switch Combined With Conventional Therapy in People With Acquired Brain Injury

NCT ID: NCT06285877

Last Updated: 2024-02-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-29

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose: to observe the possible benefits produced by conventional therapy through virtual reality with the Nintendo Switch to try to improve motivation and increase the degree of care satisfaction. The aim is to improve postural control in both seated and standing positions and to maintain and improve cognitive capacity.

Material and methods: one group (experimental group) will receive a total of 8 one-hour sessions or 16 half-hour sessions, depending on their individual needs, for 8 weeks using the Nintendo Switch. The other group (control group) will continue to receive their conventional scheduled therapy.

Measures: Abilhand, MEC-Lobo, FIST, Fugl-Meyer, Berg Balance Scale and CSQ-8.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Occupational Therapy Acquired Brain Injury Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Control Group (CG), which received their usual sessions of conventional therapy sessions, and an Experimental Group (EG), which received therapy with Nintendo Switch plus their conventional therapy sessions.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Control Group (CG) which received their usual sessions of conventional therapy.

Group Type ACTIVE_COMPARATOR

Conventional therapy sessions

Intervention Type PROCEDURE

Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.

Experimental Group

Experimental Group (EG) which received therapy with Nintendo Switch plus their usual sessions of conventional therapy.

Group Type EXPERIMENTAL

Conventional therapy sessions plus Nintendo Switch

Intervention Type PROCEDURE

Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional therapy sessions

Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.

Intervention Type PROCEDURE

Conventional therapy sessions plus Nintendo Switch

Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult men and women, over 30 years of age who have suffered an acquired brain injury.
* Mild or moderate cognitive impairment as measured by the MEC-Lobo test (score greater than 23/35).
* Regularly attend some conventional therapy (neuropsychology, physiotherapy or occupational therapy).
* Agree to participate voluntarily by signing the informed consent form.

Exclusion Criteria

* Present severe cognitive impairment as measured by the MEC-Lobo test (less than 23/35).
* Present aphasia of comprehension or expression.
* Present associated neurodegenerative pathology.
* Present any pathology underlying the acquired brain damage (diabetes, heart disease, COPD, etc.), heart disease, COPD, etc.).
* Voluntarily refuse to participate in the study.
Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Rey Juan Carlos

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Isabel Quirosa Galan

Occupational Therapist, MsC

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Isabel Quirosa Galan, MsC

Role: PRINCIPAL_INVESTIGATOR

Universidad Rey Juan Carlos

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universidad Rey Juan Carlos

Móstoles, Madrid, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Isabel Quirosa Galan, MsC

Role: CONTACT

Phone: +34655551210

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Isabel Quirosa Galan, MsC

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

291120234382023

Identifier Type: -

Identifier Source: org_study_id